Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Apr 15;56(5):412-9.
doi: 10.1097/QAI.0b013e31820fd093.

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

Mark Mirochnick  1 , Brookie M Best, Alice M Stek, Edmund V Capparelli, Chengcheng Hu, Sandra K Burchett, Steven S Rossi, Elizabeth Hawkins, Michael Basar, Elizabeth Smith, Jennifer S Read; IMPAACT 1026s Study Team
Collaborators, Affiliations
Clinical Trial

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

Mark Mirochnick et al. J Acquir Immune Defic Syndr. .

Abstract

Background: Few data are available describing atazanavir exposure during pregnancy, especially when used in combination with tenofovir, whose coadministration with atazanavir results in decreased atazanavir exposure.

Design: International Maternal Pediatric Adolescent AIDS Clinical Trials 1026 s is an ongoing, prospective, nonblinded study of antiretroviral pharmacokinetics in HIV-infected pregnant women that included 2 cohorts receiving atazanavir/ritonavir 300 mg/100 mg once daily, either with or without tenofovir.

Methods: Intensive steady-state 24-hour pharmacokinetic profiles were performed during the third trimester and at 6-12 weeks postpartum. Atazanavir was measured by reverse-phase high-performance liquid chromatography (detection limit 0.047 mcg/mL). Pharmacokinetic targets were the estimated 10th percentile atazanavir area under the concentration versus time curve [(AUC): 29.4 mcg · hr · mL-1] in nonpregnant historical controls (mean AUC = 57 mcg · hr · mL-1) and a trough concentration of 0.15 mcg/mL, the concentration target used in therapeutic drug monitoring programs.

Results: Median atazanavir AUC was reduced during the third trimester compared with postpartum for subjects not receiving tenofovir (41.9 vs. 57.9 mcg · hr · mL-1, P = 0.02) and for subjects receiving tenofovir (28.8 vs. 39.6 mcg · hr · mL-1, P = 0.04). During the third trimester, AUC was below the target in 33% (6 of 18) of women not receiving tenofovir and 55% (11 of 20) of women receiving tenofovir. Trough concentration was below the target in 6% (1 of 18) of women not receiving tenofovir and 15% (3 of 20) of women receiving tenofovir. The median (range) ratio of cord blood/maternal atazanavir concentration in 29-paired samples was 0.18 (0-0.45).

Conclusions: Atazanavir exposure is reduced by pregnancy and by concomitant tenofovir use. A dose increase of atazanavir/ritonavir to 400 mg/100 mg may be necessary in pregnant women to ensure atazanavir exposure equivalent to that seen in nonpregnant adults.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Median atazanavir concentrations during pregnancy and postpartum
Median atazanavir concentration-time curves for atazanavir without tenofovir subjects (top graph) and atazanavir with tenofovir subjects (bottom graph). The thin solid line represents the expected (50th percentile) concentration-time profile in non-pregnant adults.
Figure 3
Figure 3. Maternal delivery and cord blood atazanavir concentrations
Maternal delivery atazanavir concentrations, cord blood atazanavir concentrations and their ratio plotted against the interval between maternal dosing and delivery. Filled circles represent maternal plasma atazanavir concentration at delivery, open circle represent cord blood atazanavir concentration, filled diamonds represent the ratio of cord blood to maternal delivery atazanavir concentration.
See this image and copyright information in PMC

References

    1. Shapiro D, T R, Pollack H, et al. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery and viral load in 2895 US women (PACTG 367). Paper presented at: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; Feb. 2004; San Francisco, CA. Abstract 99.
    1. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. May 242010. [May 24, 2010]. pp. 1–117. Available at http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.
    1. Mirochnick M, Best BM, Stek AM, et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):485–491. - PMC - PubMed
    1. Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2007 Feb;51(2):783–786. - PMC - PubMed
    1. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006 Oct 3;20(15):1931–1939. - PubMed

Publication types

MeSH terms